Omeros corporation reports first quarter 2022 financial results

Seattle--(business wire)--omeros corporation (nasdaq: omer), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the first quarter ended march 31, 2022, which include: on december
OMER Ratings Summary
OMER Quant Ranking